The Claim
Baseline selenoprotein P levels in critically ill cancer and cardiac patients are lower than baseline selenoprotein P levels in healthy European populations.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Critically ill cancer and cardiac patients have lower levels of selenoprotein P in their blood before treatment compared to healthy people in Europe.
See the scientific wording
Baseline selenoprotein P levels in critically ill cancer and cardiac patients are lower than those in healthy European populations, suggesting these populations may have suboptimal selenium status prior to therapeutic intervention.
The liver makes a protein called selenoprotein P to carry selenium through the blood. When there is not enough selenium in the body, the liver cannot make enough of this protein. In critically ill cancer and cardiac patients, selenium levels are low, so the liver produces less selenoprotein P. When selenium is given directly into the bloodstream, the liver quickly uses it to make more selenoprotein P, proving that the low levels before treatment were due to insufficient selenium, not a broken production system.
What the research says
1 studyThis study shows that when sick patients get a lot of selenium, their SELENOP levels go up — meaning low SELENOP levels before treatment probably mean they didn’t have enough selenium to begin with.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.